Industry
Biotechnology
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 10:57 am
Portfolio Pulse from Benzinga Insights
August 06, 2024 | 8:01 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 6:09 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 11:58 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 11:57 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 11:46 am
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 9:30 am
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 5:01 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 11:05 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.